Norges Bank’s LENZ Therapeutics LENZ Stock Holding History

Norges Bank’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-79,167	Closed	-$2.83M	–	2182
2022 Q1	$2.83M	Hold	79,167	–	–	﹤0.01%	1945
2021 Q4	$6.89M	Hold	79,167	–	–	﹤0.01%	1853
2021 Q3	$9.08M	Sell	79,167 -20,833	-21%	-$3.09M	﹤0.01%	1800
2021 Q2	$21.5M	Buy	+100,000	New	+$17.4M	﹤0.01%	1491

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Norges Bank's LENZ Position: Q2 2022 in Review

Norges Bank sold out of LENZ Therapeutics (LENZ) in Q2 2022, closing a stake of 79,167 shares — an estimated $2.83M sold.

Norges Bank first reported a position in LENZ in Q2 2021 and held it in 4 quarters. The position peaked at $21.5M in Q2 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q2 2022.

Norges Bank reported no remaining LENZ Therapeutics position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 79,167 LENZ Therapeutics shares in Q2 2022, an estimated $2.83M.
Norges Bank first reported a position in LENZ Therapeutics in Q2 2021 and held it in 4 quarters.
Norges Bank's LENZ Therapeutics position peaked at $21.5M in Q2 2021.
63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.